
Alvotech Holdings S.A
ALVO | LuxSE
Overview
Corporate Details
- ISIN(s):
- LU2458332611
- LEI:
- 222100DCZBOWV5DZ8372
- Country:
- Luxembourg
- Address:
- 9, RUE DE BITBOURG, L-1273 LUXEMBOURG
- Website:
- https://www.alvotech.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
We specialize in making biosimilars – to improve lives by expanding access to affordable biologic medicines. We are purpose-driven and passionate about what we do. We have a deep appreciation for the positive impact biologic medicines have had on health care. From insulin to vaccines to monoclonal antibody cancer therapies, biologic medicines are revolutionizing the way we treat diseases and improve patient lives. It is our aim to broaden the availability of these important biologic medicines to patients around the world by developing and manufacturing high-quality, cost-competitive biosimilars. Our commitment to the promise of biosimilars is foundational to our approach, our culture and the strong sense of purpose that inspires us to work smarter and faster towards this mission. We are driven by passion - if there is a proven biologic medicine, we believe it should be accessible to all patients in need.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-05-26 10:01 |
Directors' Dealings
Notification Managers Transaction - Alvotech - Alvogen Lux Holdings S.à r.l.
|
English | 84.5 KB | |
2025-05-20 09:24 |
Directors' Dealings
Managers' Transaction Notification R. Davies (20250516)
|
English | 84.1 KB | |
2025-05-13 17:44 |
Regulatory News Service
pdf1278040195305217091
|
English | 84.5 KB | |
2025-05-12 10:18 |
Regulatory News Service
Managers' Transaction Notification (20250512)
|
English | 55.7 KB | |
2025-04-30 20:07 |
Regulatory News Service
222100DCZBOWV5DZ8372-2024-12-31-en (2)
|
English | 1.3 MB | |
2025-04-30 20:07 |
Regulatory News Service
4be7257a-c4d2-4fa3-bc77-2b60162f8a38
|
English | 10.0 MB | |
2025-01-15 22:00 |
Directors' Dealings
ATP Holdings ehf. - Managers' Transaction Notification (PCA)
|
English | 49.4 KB | |
2024-12-30 23:41 |
Directors' Dealings
pdf5009312744798760428 (1)
|
English | 49.5 KB | |
2024-10-30 12:30 |
Earnings Release
Alvotech to Report Financial Result..
|
Icelandic | 3.9 KB | |
2024-10-30 12:30 |
Earnings Release
Alvotech to Report Financial Result..
|
English | 5.8 KB | |
2024-10-10 10:01 |
Regulatory News Service
European Medicines Agency Confirms Acceptance of Marketing Application for AVT0…
|
Icelandic | 8.7 KB | |
2024-10-10 10:01 |
Regulatory News Service
European Medicines Agency Confirms Acceptance of Marketing Application for AVT0…
|
English | 14.4 KB | |
2024-10-01 20:03 |
Interim Report
Unaudited Consolidated Financial Statements Q2 2024
|
English | 345.5 KB | |
2024-08-29 23:22 |
Regulatory News Service
Registration Statement Declared Effective
|
Icelandic | 1.3 KB | |
2024-08-29 23:22 |
Prospectus
Registration Statement Declared Effective
|
English | 1.2 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
1NKEMIA | Spain | IKM | |
![]() |
2cureX AB | Sweden | 2CUREX | |
![]() |
4SC AG | Germany | VSC | |
![]() |
Abera Bioscience AB | Sweden | ABERA | |
![]() |
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
![]() |
AB Science | France | AB | |
![]() |
Acticor Biotech | France | ALACT | |
![]() |
Active Biotech | Sweden | ACTI | |
![]() |
AcuCort AB | Sweden | ACUC |